加载中
NASDAQHealthcareMedical - Diagnostics & Research
最新数据
US$4.20
−US$0.11 · -2.55%
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
前收盘价
US$4.20
−US$0.11 · -2.55%
盘前
US$4.17
−US$0.03 · -0.71%
10月13日 4:00 ET
盘中时间采用ET。市场数据可能有所延迟。
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
日内区间
当前US$4.20
52周区间
当前US$4.20
盘中时间采用ET。市场数据可能有所延迟。
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
日内区间
当前US$4.20
52周区间
当前US$4.20
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 8.25亿 USD | 8.38亿 USD | 7.53亿 USD | 6.78亿 USD | 6.91亿 USD |
| 销货成本 | 2.48亿 USD | 2.52亿 USD | 2.36亿 USD | 2.02亿 USD | 1.98亿 USD |
| 毛利 | 5.77亿 USD | 5.85亿 USD | 5.17亿 USD | 4.76亿 USD | 4.93亿 USD |
| 研究与开发 | 1.07亿 USD | 1.13亿 USD | 8870万 USD | 8540万 USD | 8190万 USD |
| 销售、一般及管理费用 | 5.38亿 USD | 5.6亿 USD | 5.73亿 USD | 5.15亿 USD | 5.38亿 USD |
| 营业费用 | 6.44亿 USD | 6.73亿 USD | 6.62亿 USD | 6亿 USD | 6.84亿 USD |
| 利息收入 | 180万 USD | 170万 USD | 250万 USD | 260万 USD | 70万 USD |
| 利息支出 | 1050万 USD | 280万 USD | 290万 USD | 320万 USD | 660万 USD |
| 折旧和摊销 | 5370万 USD | 6120万 USD | 6190万 USD | 5270万 USD | 6280万 USD |
| 营业利润 | −6780万 USD | −8800万 USD | −1.45亿 USD | −1.24亿 USD | −1.91亿 USD |
| 净利润 | −3.66亿 USD | −1.27亿 USD | −2.63亿 USD | −1.12亿 USD | −2720万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$3.92
下跌空间 6.67%| 行动 | 除息日 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2009年7月1日 | US$1.75Monthly | — | — |
股息 | 2009年6月15日 | US$1.75Monthly | — | — |
除息 2009年7月1日
US$1.75
Monthly
除息 2009年6月15日
US$1.75
Monthly
报告持有此股票敞口的交易所交易基金。
State Street SPDR S&P Biotech ETFXBI1202.05万0.12%103.03亿 USD0.35%US$151.4-1.54%
iShares Russell 2000 ETFIWM1026.63万0.01%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Morningstar Total Stock Market ETFVTI927.9万0.00%2.3万亿 USD0.03%US$381.57-0.10%
Vanguard Extended Market ETFVXF356.47万0.00%954亿 USD0.05%US$233.52-0.63%
Fidelity Enhanced Small Cap ETFFESM350.6万0.05%64.1亿 USD0.28%US$45.24-0.48%
iShares Biotechnology ETFIBB295.62万0.03%108.2亿 USD0.44%US$204.26-1.08%
Schwab U.S. Small-Cap ETFSCHA212.52万0.01%217.13亿 USD0.03%US$32.66-0.40%
Schwab Fundamental U.S. Small Company Index ETFFNDA197.01万0.02%87.72亿 USD0.25%US$35.60-0.06%State Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHASchwab Fundamental U.S. Small Company Index ETFFNDAAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
